Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson

Sales to Customers

Sales to Customers %Chg

Sales to Customers Common Size

Cost of Products Sold

Cost of Products Sold %Chg

Cost of Products Sold Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Selling, Marketing and Administrative Expenses

Selling, Marketing and Administrative Expenses %Chg

Selling, Marketing and Administrative Expenses Common Size

Research and Development Expense

Research and Development Expense %Chg

Research and Development Expense Common Size

In-Process Research and Development Impairments

In-Process Research and Development Impairments %Chg

In-Process Research and Development Impairments Common Size

Interest Income

Interest Income %Chg

Interest Income Common Size

Interest Expense, Net of Portion Capitalized

Interest Expense, Net of Portion Capitalized %Chg

Interest Expense, Net of Portion Capitalized Common Size

Other Expense, Net

Other Expense, Net %Chg

Other Expense, Net Common Size

Interest (Income) Expense, Net

Interest (Income) Expense, Net %Chg

Interest (Income) Expense, Net Common Size

Restructuring Expense

Restructuring Expense %Chg

Restructuring Expense Common Size

Earnings Before Provision for Taxes on Income

Earnings Before Provision for Taxes on Income %Chg

Earnings Before Provision for Taxes on Income Common Size

Provision for Taxes on Income

Provision for Taxes on Income %Chg

Provision for Taxes on Income Common Size

Net Earnings

Net Earnings %Chg

Net Earnings Common Size

Restructuring

Restructuring %Chg

Restructuring Common Size

Provision for/(Benefit From) Taxes on Income

Provision for/(Benefit From) Taxes on Income %Chg

Provision for/(Benefit From) Taxes on Income Common Size

Net Earnings from Continuing Operations

Net Earnings from Continuing Operations %Chg

Net Earnings from Continuing Operations Common Size

Net Earnings/(Loss) from Discontinued Operations, Net of Tax

Net Earnings/(Loss) from Discontinued Operations, Net of Tax %Chg

Net Earnings/(Loss) from Discontinued Operations, Net of Tax Common Size

Net Earnings from Discontinued Operations, Net of Tax

Net Earnings from Discontinued Operations, Net of Tax %Chg

Net Earnings from Discontinued Operations, Net of Tax Common Size

Continuing Operations - Basic

Continuing Operations - Basic %Chg

Continuing Operations - Basic Common Size

Discontinued Operations - Basic

Discontinued Operations - Basic %Chg

Discontinued Operations - Basic Common Size

Basic

Basic %Chg

Basic Common Size

Net Earnings per Share from Continuing Operations

Net Earnings per Share from Continuing Operations %Chg

Net Earnings per Share from Continuing Operations Common Size

Net Earnings per Share from Discontinued Operations

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Discontinued Operations

Net Income Attributable to Discontinued Operations %Chg

Net Income Attributable to Discontinued Operations Common Size

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Jun '25	Dec '24	Jun '24	Dec '23	Jul '23	Jan '23
Total Revenues	45,636	44,991	44,991	42,746	42,413	39,935
Total Revenues %Chg	1.4%	5.3%	6.1%	7%	-10.6%	20.6%
Sales to Customers
Cost of Sales	14,985	7,128	14,091	13,404	13,149	12,256
Cost of Products Sold
Gross Profit	30,651	15,392	30,900	29,342	29,264	27,679
Gross Profit
Gross Profit Margin	67.2%	69.5%	68.7%	68.6%	69%	69.3%
Selling, General & Administrative Expenses	11,001	6,453	11,931	11,210	10,302	10,314
Selling, Marketing and Administrative Expenses
Research & Development Expenses	6,741	5,298	10,250	7,927	7,158	7,195
Research and Development Expense
Other Operating Expenses	81	100	100	478	324	313
In-Process Research and Development Impairments
Restructuring
Operating Profit	12,828	3,541	8,619	9,727	11,480	9,857
Operating Margin	28.1%	27.8%	19.2%	22.8%	27.1%	24.7%
Interest and Investment Income	592	—	1,332	374	524	150
Interest Income
Interest Expense	-512	144	-1,089	20	-429	26
Interest Expense, Net of Portion Capitalized
Interest (Income) Expense, Net
Non-Operating Income	7,214	161	-1,637	-78	-6,556	-1,021
Other Expense, Net
Total Non-Operating Income	7,294	305	-1,394	316	-6,461	-845
Income Before Provision for Income Taxes	20,122	7,225	7,225	10,043	5,019	9,012
Earnings Before Provision for Taxes on Income
Earnings Before Provision for Taxes on Income
Provision for Income Taxes	3,586	456	1,100	1,602	134	1,475
Provision for Taxes on Income
Provision for/(Benefit From) Taxes on Income
Consolidated Net Income	16,536	3,431	14,066	8,441	4,885	7,537
Net Earnings from Continuing Operations
Net Income Attributable to Discontinued Operations	—	—	—	21,719	191	148
Net Earnings from Discontinued Operations, Net of Tax
Net Income Attributable to Common Shareholders	16,536	3,431	6,125	30,077	5,076	7,978
Net Earnings
Basic EPS	6.9	—	5.8	12	2	2.9
Diluted EPS	6.8	—	5.8	11.9	1.9	2.9
Basic Weighted Average Shares Outstanding	2,406.8	—	2,407.5	2,476.8	2,602	2,639
Total Shares Outstanding	2,406.8	2,406.9	2,407	2,407.2	2,613.6	2,613.6
Diluted Weighted Average Shares Outstanding	2,421.5	—	2,426.1	2,490.2	2,615.6	2,655.7
EBITDA	16,543	19,524	12,216	13,399	15,294	13,314
Effective Tax Rate	17.8%	11.9%	15.2%	16%	2.7%	16.4%